Biogen and Samsung make deal for marketing anti-TNF biosimilars

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Biogen and Samsung make deal for marketing anti-TNF biosimilars

Biosimilars/News | Posted 17/01/2014 0 Post your comment

US biotechnology company Biogen Idec (Biogen) and Korean electronics giant Samsung announced on 17 December 2013 that Biogen has exercised its right to enter into an agreement to commercialize anti-tumour necrosis factor (TNF) biosimilar product candidates in Europe.

Biogen will manufacture and market in Europe a number of anti-TNF biosimilars for inflammatory diseases such as rheumatoid arthritis and Crohn’s disease. The agreement is part of the joint venture (called Samsung Bioepis) Biogen made back in December 2011 with Samsung’s specialized biologicals unit, Samsung Biologics [1].

Mr Tony Kingsley, Biogen’s Executive Vice President of Global Commercial Operations viewed the deal as ‘a unique opportunity for us to leverage our experience in developing and manufacturing high-quality biologic[al]s in therapeutic areas where we are deeply focused’. While Mr Christopher Hansung Ko, CEO of Samsung Bioepis, believes that ‘this agreement will further serve as a solid foundation for Samsung Bioepis to develop into a worldwide biosimilar leader’.

Samsung plans to launch biosimilars by 2015 at half the price that patients in the US and Europe currently pay and is expecting to achieve annual revenues from biologicals of US$1.8 trillion by 2020 [2].

References

1. GaBI Online - Generics and Biosimilars Initiative. Samsung makes biosimilars deal with Biogen Idec [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Jan 17]. Available from: www.gabionline.net/Biosimilars/News/Samsung-makes-biosimilars-deal-with-Biogen-Idec

2. GaBI Online - Generics and Biosimilars Initiative. Samsung halts biosimilar rituximab development [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Jan 17]. Available from: www.gabionline.net/Biosimilars/News/Samsung-halts-biosimilar-rituximab-development

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: Biogen Idec, Samsung Bioepis